Stockwinners Market Radar for June 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment sold 18K shares of DraftKings today

19:36 EDT FDA accepts BLAs for Vertex Pharmaceuticals' investigational treatment exa-cel - Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced that the FDA has accepted the Biologics License Applications, or BLAs for the investigational treatment exagamglogene autotemcel, or exa-cel, for severe sickle cell disease and transfusion-dependent beta thalassemia. The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act target action dates of December 8, 2023, and March 30, 2024, respectively. Updated data from the pivotal trials supporting the regulatory submissions will be presented at the Annual European Hematology Association Congress on June 11, 2023.

18:48 EDT Univar announces regulatory approval update on Apollo transaction - Univar Solutions (UNVR) provided a regulatory approval update for the company's pending acquisition by affiliates of funds managed by affiliates of Apollo (APO). Antitrust regulatory approvals have now been received from the United States, Brazil, Canada, China, the European Union and Mexico. Additionally, the company has received foreign direct investment regulatory approval from Italy. Pending regulatory approvals include antitrust approval in Turkey and foreign direct investment approvals from the United States, France and Spain. Assuming timely satisfaction of necessary closing conditions, the transaction is expected to close around the middle of the third quarter of 2023.

17:57 EDT ACI Worldwide CEO buys $1.02M in common stock as part of option expiry - In a regulatory filing, ACI Worldwide disclosed that its CEO Thomas Warsop bought 43K shares of common stock on June 6th as part of option expiry.

17:39 EDT Dover CFO sells $2.47M in common stock - In a regulatory filing, Dover disclosed that its CFO Brad Cerepak sold 17.8K shares of common stock on June 6th in a total transaction size of $2.47M.

17:32 EDT Fastly exec sells $3.51M in common stock - In a regulatory filing, Fastly disclosed that its Chief Architect Artur Bergman sold 209.7K shares of common stock on June 6th in a total transaction size of $3.51M.

17:13 EDT Raytheon Technologies awarded $372.14M Navy contract - Raytheon was awarded a $372.14M cost-plus-fixed-fee, cost reimbursable, firm-fixed-price, indefinite-delivery/indefinite-quantity contract. This contract provides for updates, improvements, and enhancements of tactical capabilities, sensor instrumentation, and instrumentation interfaces in support of F/A-18 and EA-18G software blocks. Work is expected to be completed in June 2028. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to Federal Acquisition Regulation 6.302-1. The Naval Air Warfare Center Weapons Division, China Lake, California, is the contracting activity.

17:09 EDT Pennsylvania American Water to buy Farmington Water and Wastewater Systems - Pennsylvania American Water announced that it has signed an agreement with Farmington Township, Clarion County, to purchase the township's water and wastewater systems for $5.545 million. The systems serve 1,017 customers in Farmington Township.

16:42 EDT Oil-Dri Corporation of America raises quarterly dividend by 4% - The Board of Directors of Oil-Dri Corporation of America declared quarterly cash dividends of $0.29 per share of the Company's Common Stock and $0.218 per share of the Company's Class B Stock, an approximate 4% increase for both classes of stock. The dividends declared will be payable on August 25, 2023 to stockholders of record at the close of business on August 11, 2023.

16:33 EDT Charles River enters plasmid DNA manufacturing alliance with INADcure - Charles River Laboratories and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal Dystrophy, INAD, and other forms of PLA2G6-related neurodegeneration, announced a plasmid DNA manufacturing alliance. The collaboration will leverage Charles River's market leading contract development and manufacturing organization expertise in High Quality plasmid DNA production, to manufacture its leading candidate for Phase I/II clinical trials. In INAD patients, a mutation or genetic alteration in the PLA2G6 gene causes mitochondrial and axonal membrane defects that lead to neuronal damage with axonal swellings and accumulation of pre-synaptic spheroids.

16:28 EDT Cohen & Steers reports preliminary AUM $77.9B as of May 31 - Cohen & Steers reported preliminary assets under management of $77.9B as of May 31, a decrease of $3.1B from assets under management at April 30. The decrease was due to market depreciation of $2.4B, net outflows of $461M and distributions of $181M.

16:22 EDT Sientra announces FDA-clearance of next generation AlloX2 Pro tissue expander - Sientra announced that the Food and Drug Administration has granted a 510k-clearance for the Company's novel, patented1 AlloX2 Pro Tissue Expander. Building upon the proprietary dual port technology of the Company's ground-breaking AlloX2 tissue expander, the AlloX2 Pro expands this platform by removing 95% of the metal traditionally associated with tissue expander ports. This innovation allows the AlloX2 Pro to be labeled as MRI-conditional, making it the only tissue expander cleared in the United States for exposure to magnetic resonance imaging, an important screening tool for breast reconstruction patients. Other innovative features of the AlloX2 Pro include minimal interference with radiation therapy for post-mastectomy patients,2 faster port filling and drainage, and a softer drain for enhanced patient comfort."I am extremely proud to have partnered with Sientra to bring the AlloX2 Pro to market," commented Dr. Thomas McClellan, a board-certified plastic surgeon in West Virginia and inventor of AlloX2. "Sientra's commitment to women's health and technological development in breast reconstruction made them the natural choice to make this important innovation in the treatment of post-mastectomy women a reality."

16:19 EDT Steel Partners names Joseph Martin chief administrative officer - Steel Partners Holdings announced the appointment of Joseph Martin as Chief Administrative Officer and Chief Legal Officer and Maria Reda as General Counsel. These appointments will further strengthen the company's strategic planning, administrative, and legal functions, supporting its growth and success. In his role as Chief Administrative Officer, Mr. Martin will provide expert guidance and strategic direction to the executive team. "We are delighted to welcome Joe Martin back to Steel Partners as our Chief Administrative Officer and Chief Legal Officer, and to announce Maria Reda as our General Counsel," said Executive Chairman Warren Lichtenstein. "Their combined expertise and leadership will enable us to navigate a rapidly evolving business landscape effectively."

16:16 EDT Hydrofarm enters exclusive alliance with CEA advisors - Hydrofarm announced that it has entered into an exclusive strategic alliance with CEA Advisors, a global design/build consultancy to the vertical farming industry and manufacturer of Growtainers and Growracks, to accelerate their expansion into the growing and evolving CEA space for both food and non-food production. Hydrofarm's Innovative Growers Equipment, or IGE, commercial division will serve as the North American manufacturing and marketing hub for Growtainers and Growracks. IGE's Sycamore, Illinois facility combines manufacturing, research and development, and warehouse space serving the global market.

16:13 EDT DocuSign jumps 13% to $66.21 after Q1 results beat, FY24 revenue view raised

16:12 EDT Offerpad Solutions announces 1-for-15 reverse stock split - Offerpad Solutions announced that it will effect a 1-for-15 reverse stock split of its Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, that will become effective at 5:00 p.m. Eastern Time on June 12, 2023. The Company expects that its Class A Common Stock will open for trading on the New York Stock Exchange on a reverse split-adjusted basis on June 13, 2023 under the existing trading symbol "OPAD". The new CUSIP number for the Class A Common Stock following the Reverse Stock Split will be 67623L 307. The Company's publicly traded warrants will continue to be traded on the NYSE under the symbol "OPADWS" and the CUSIP number for the warrants will remain unchanged. However, under the terms of the applicable warrant agreement, the number of shares of Class A Common Stock issuable on exercise of each warrant will be proportionately decreased. Specifically, following effectiveness of the Reverse Stock Split, every 15 shares of Class A Common Stock that may be purchased pursuant to the exercise of public warrants now represents one share of Class A Common Stock that may be purchased pursuant to such warrants. Accordingly, for the Company's warrants trading under the symbol "OPADWS", every 15 warrants will be exercisable for one share of Class A Common Stock at an exercise price of $172.50 per share of Class A Common Stock.

16:09 EDT Mission Produce expects volumes to be 20% higher in Q3 - The company said, "For the third quarter of fiscal year 2023, the Company is providing the following industry outlook that will drive performance: The industry continues to expect volumes to be approximately 20% higher in the fiscal 2023 third quarter versus the prior year period, primarily due to the combination of California's harvest shifting to the third quarter versus the second quarter last year, a strong Peruvian harvest outlook, and a larger off-bloom Mexican harvest. Expectations for exportable avocado production from Mission's owned farms is in the range of 125 million to 135 million pounds, the sale of which the Company anticipates will be more heavily weighted to the fiscal fourth quarter. Pricing is expected to be consistent on a sequential basis, but lower on a year-over-year basis by approximately 35-40% compared to the $2.03 per pound average experienced in third quarter of fiscal 2022."

16:08 EDT Planet Labs reports Q1 customer count up 9% from last year - For Q1: "Percent of Recurring Annual Contract Value (ACV) for the first quarter was 93%. End of Period Customer Count increased 9% year-over-year to 903 customers. First quarter Gross Margin expanded to 56%, compared to 45% in the first quarter of fiscal year 2023."

16:06 EDT GM CEO says will discuss 'future of EV charging' in event with Tesla CEO - General Motors (GM) CEO Mary Barra tweeted: "Please join me and @elonmusk on Twitter Spaces at 4:30 p.m. ET" along with a link to a Twitter Spaces event to "discuss the future of EV charging." Reference Link

16:02 EDT AngioDynamics sells Dialysis product portfolio and BioSentry for $100M - AngioDynamics "announced that it has completed the sale of its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems, Inc. for $100 million in cash. The transaction consists of AngioDynamics' DuraFlow(TM), DuraMax(R), Evenmore(R), Schon XL(R), Trio-CT(R) and Vaxel Plus Hemodialysis Catheter brands, and BioSentry(TM) Tract Sealant System Biopsy brand. This combined portfolio of products contributed approximately $32 million in sales in AngioDynamics' Fiscal Year 2023. AngioDynamics intends to use net proceeds to eliminate its existing debt and support further strategic investments in growth and profitability. The divested assets are included in the Company's Med Device Business and do not have a significant amount of direct costs. As a result, the transaction will be dilutive to adjusted earnings per share and is expected to be slightly dilutive to corporate gross margins."

16:00 EDT Expensify to join Russell 3000 index - Expensify "announced that the company will join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution according to a preliminary list of additions posted May 19. Expensify is set to join the broad-market Russell 3000(R) Index, effective after the US market opens on June 26."

15:45 EDT Newmont Mining trading resumes

15:24 EDT Twilio to sell ValueFirst Business to Tanla - Twilio is announcing that it has entered into a definitive agreement for Tanla to purchase Twilio's ValueFirst business. "The agreement is subject to customary closing conditions and we expect to close in July 2023," Twilio stated in a post to its corporate blog. "Twilio acquired ValueFirst India in 2021 with the primary intent to accelerate growth opportunities in India, as well as explore other products and services that ValueFirst has been delivering. While India is still a strategic market for Twilio, we believe allocating our resources to other strategic priorities may have a greater impact on the future of our business. We also believe that Tanla's acquisition of ValueFirst will better leverage the talent and business portfolio that ValueFirst has created and is the best route forward to successfully serve customers in India in the short and long term," the blog stated. Reference Link

15:02 EDT California DMV issues autonomous vehicle deployment permit to Mercedes-Benz - The California Department of Motor Vehicles issued an autonomous vehicle deployment permit to Mercedes-Benz USA, allowing the company to offer its DRIVE PILOT automated driving system on designated California highways under certain conditions without the active control of a human driver. "Mercedes-Benz is the fourth company to receive an autonomous vehicle deployment permit in California and the first authorized to sell or lease vehicles with an automated driving system to the public," the DMV stated. Reference Link

14:10 EDT Meta's WhatsApp announces Channels feature for broadcast messages - Meta's WhatsApp introduced Channels, a private way to receive important updates from people and organizations, right within WhatsApp. "We're building Channels in a new tab called Updates - where you'll find Status and channels you choose to follow - separate from your chats with family, friends, and communities," the company said. "Channels are a one-way broadcast tool for admins to send text, photos, videos, stickers, and polls. To help you select channels to follow, we're building a searchable directory where you can find your hobbies, sports teams, updates from local officials, and more. You can also get to a channel from invite links sent in chats, e-mail, or posted online. We're aspiring to build the most private broadcast service available. This starts by protecting the personal information of both admins and followers. As a channel admin, your phone number and profile photo won't be shown to followers. Likewise, following a channel won't reveal your phone number to the admin or other followers. Who you decide to follow is your choice and it's private. Similar to how we build messaging, we don't believe Channel updates should have to stick around forever. So we'll only store channel history on our servers for up to 30 days and we'll add ways to make updates disappear even faster from follower's devices. Admins will also have the option to block screenshots and forwards from their channel. Lastly, we'll make it possible for admins to decide who can follow their channel and whether they want their channel to be discoverable in the directory or not. Given the aim of Channels is to reach a wide audience, channels are not end-to-end encrypted by default. We do think there are some cases where end-to-end encrypted channels to a limited audience might make sense, such as a non profit or health organization, and we're exploring this as a future option as well." The company said that, to kick off Channels, it is working with global voices and select organizations in Colombia and Singapore, where Channels will first be available, to build, learn, and adapt the experience. "We'll bring Channels to more countries and the ability for anyone to create a channel over the coming months," WhatsApp added. Reference Link

14:02 EDT TerrAscend announces agreement to acquire medical dispensary in Maryland - TerrAscend announced that on June 7 it entered into a definitive agreement to acquire Derby 1, d/b/a "Peninsula Alternative Health," a medical dispensary in Maryland. The transaction will add a second dispensary to the company's Maryland footprint in advance of adult-use sales, which will begin on July 1, TerrAscend stated. Under the terms of the agreement, TerrAscend will acquire Peninsula Alternative Health for total consideration of $22.1M, including $1.5M in cash, with the remainder in a combination of existing debt, a seller's note, and stock. The transaction, which is expected to be immediately accretive to TerrAscend on an EBITDA and cashflow basis, is subject to customary closing conditions, including regulatory approval. "Adding a second, high-performing medical dispensary in Maryland is an important step in our strategy to become a market leader in the state. We expect Peninsula to quickly become one of our highest performing dispensaries nationwide. With less than 30 days until the launch of adult use in Maryland, we are focused on additional acquisitions and reaching the four-dispensary cap as our northeast business unit will soon be operating in Maryland under the same successful business model we built in NJ," said Jason Wild, Executive Chairman of TerrAscend.

14:00 EDT Trials 'back on track' post-COVID, 180 Life Sciences CEO Jim Woody says

13:55 EDT Capcom's 'Resident Evil Village' passes 8M units since 2021 release - Capcom (CCOEY) said that survival horror game "Resident Evil Village" has surpassed 8M units sold. The game launched in 2021 for Xbox One (MSFT), PlayStation 4 (SONY), PC, PS4, and Xbox Series X/S, and later launched for macOS (AAPL) and Nintendo Switch (NTDOY) in 2022. Reference Link

13:13 EDT General Motors to invest $500M-plus in Arlington Assembly for future SUVs - General Motors announced plans to invest more than $500M in Arlington Assembly to prepare the plant for production of future internal combustion engine full-size SUVs, subject to successful discussions with local government officials. This investment will enable the company to strengthen its industry-leading full-size SUV business. The announcement brings GM's U.S. manufacturing and parts distribution facility investment commitments to more than $31B since 2013. Through this more than half-a-billion-dollar investment, Arlington Assembly will receive new tooling and equipment in its stamping, body shop and general assembly areas.

12:35 EDT Amazon announces support for cannabis policy reform - Amazon.com announced its support for reforming the nation's cannabis policy. In a statement written by Beth Galetti, Senior Vice President of People Experience and Technology at Amazon, the company said: "Pre-employment marijuana testing has disproportionately affected communities of color by stalling job placement and, by extension, economic growth, and we believe this inequitable treatment is unacceptable...That's why we strongly believe the time has come to reform the nation's cannabis policy, and we are committed to helping lead the effort...We are enthused by the notable momentum in the country toward recognizing that today's status quo is unfair and untenable. We look forward to working with Congress and other supporters to secure necessary reform of the nation's cannabis laws." Publicly traded companies in the space cannabis include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), India Globalization Capital (IGC), Tilray (TLRY), Trees Corporation (CANN), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE). Reference Link

12:32 EDT Wesdome Gold Mines suspends activities at Kiena Mine amid forest fires - Wesdome Gold Mines has temporarily suspended underground activities and surface exploration activities at the Kiena Mine in Val d'Or, Quebec. Warwick Morley-Jepson, Board Chair and Interim CEO, commented "The safety of our employees and contractors is always our first priority. At this point there are no fires within at least a 50 kilometre radius at Kiena, however the wind direction changed overnight and the plumes of smoke generated by these fires pose a potential risk to the well-being of our site personnel. Consequently, a proactive decision has been made to temporarily suspend underground operations, which will be evaluated on a shift-by-shift basis. Some essential surface activities such as operation of the mill, shaft maintenance and the placement of paste fill underground can continue safely. We are closely monitoring the situation in collaboration with local authorities and a dedicated fire watch crew. Production is not expected to be materially affected at this time. The situation being highly variable given the influence of the wind, further updates will be provided if and when material change is forecast. Importantly, no infrastructure or power supply systems at either operation has been affected, and Eagle operations are running as normal with the closest fire more than 100 kilometres away and there being no threat of smoke in the area at this time. On behalf of the team, we would like to extend our sincere gratitude to all firefighters and emergency workers for their tireless response to this difficult situation."

12:10 EDT Playtika Holding Corp trading resumes

12:01 EDT Centene selected by OHCA for statewide contracts for SoonerSelect - Centene has been selected by the Oklahoma Health Care Authority for statewide contracts to provide managed care for the SoonerSelect and SoonerSelect Children's Specialty Plan programs.The SoonerSelect program will provide physical and behavioral healthcare, as well as pharmacy benefits, to more than 840,000 Oklahoma Medicaid recipients.The SoonerSelect Children's Specialty plan provides behavioral health, physical health and pharmacy benefits to Oklahoma's children served by the Department of Human Services, including children in foster care and receiving adoption assistance, as well as those involved in the juvenile justice system. The SoonerSelect and SoonerSelect Children's Specialty Plan Program have a one-year contract term with five, one-year renewal options.

12:00 EDT Smartsheet falls -18.6% - Smartsheet is down -18.6%, or -$9.13 to $39.87.

12:00 EDT Rev Group rises 16.2% - Rev Group is up 16.2%, or $1.91 to $13.67.

12:00 EDT Carvana rises 27.7% - Carvana is up 27.7%, or $4.30 to $19.83.

11:31 EDT Glass Lewis recommends Mind Medicine investors vote for company nominees - Mind Medicine announced that proxy advisory firm Glass, Lewis & Co. recommends shareholders vote for the election of all of MindMed's six director nominees to the Board of Directors at the upcoming Annual Meeting of Shareholders, scheduled for June 15, 2023. Previously,proxy advisory firm Institutional Shareholder Services Inc. also recommended in favor of all six of the company's director nominees. In its report recommending support for MindMed's nominees, Glass Lewis notes: "In our view, the incumbent leadership appears to be executing a reasonable and logical strategy to advance development of MindMed's most promising therapeutic candidates, including an approach to the development of MM-120 for the treatment of GAD in a manner that has been endorsed by a third-party FDA regulatory consultant." "(W)e find that the Dissident has not offered a compelling strategy or actionable suggestions to improve the Company's financial or operating performance beyond what the incumbent leadership is already undertaking." Robert Barrow, Chief Executive Officer and Director of MindMed, stated: "Glass Lewis joining ISS in recommending support for all our director nominees is validation of our strategy and the quality of our Board. As both independent proxy advisory firms concluded, MindMed's directors possess the relevant experience and backgrounds to lead the Company through this pivotal period as we approach our first key data milestones. Notably, Glass Lewis also agreed with ISS that FCM has not put forth a superior strategy or a compelling case for change. We encourage shareholders to vote for all six of our nominees and help us maintain our forward progress to deliver on our mission for patients and shareholders."

11:22 EDT Toro Company continues to see gross margin improvement in FY23 vs. FY22 - Comments taken from Q2 earnings conference call.

11:20 EDT Loop Media announces strategic partnership with Pypestream - Loop Media and Pypestream, a self-service automation platform with an all-in-one cloud messaging and conversational AI, announced a strategic partnership that brings AI to Loop Media's curated entertainment business venue experience. "Helping our venue partners achieve a better customer experience is at the heart of Loop Media's mission," said Liam McCallum, Chief Product & Technical Officer of Loop Media. "We believe partnering with Pypestream to deliver a better customer experience for our rapidly growing screen footprint using their proprietary technology, gives Loop Media the AI edge on our competition."

11:13 EDT Acadia Pharmaceuticals announces publication of Phase 3 LAVENDER results - Acadia Pharmaceuticals announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE in patients with Rett syndrome five to 20 years of age. In the study, treatment with DAYBUE demonstrated statistically significant improvement compared to placebo on both co-primary efficacy endpoints, with the following key findings: The mean change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire total score was -5.1 and -1.7 in the DAYBUE and placebo groups, respectively. Based on the mixed-effects model for repeated measures analysis, the least squares mean change from baseline to week 12 in the RSBQ total score was statistically significantly greater with DAYBUE, with an LSM placebo-subtracted difference of -3.1, a 95% confidence interval of -5.7 to -0.6, a p-value of 0.0175, and a Cohen's d effect size of 0.37. Change from baseline for all RSBQ domain subscores were numerically in favor of DAYBUE. At week 12 in the DAYBUE and placebo groups, respectively, the mean Clinical Global Impression-Improvement scores were 3.5 and 3.8. MMRM analysis showed a statistically significant improvement with DAYBUE compared with placebo at week 12, with a LSM difference of -0.3, a 95% CI of -0.5 to -0.1, a p-value of 0.0030 and a Cohen's d effect size of 0.47. A subgroup analysis showed a similar benefit with DAYBUE over placebo irrespective of age, baseline RSBQ severity, and category of documented disease-causing MECP2 mutation severity.

11:02 EDT 180 Degree Capital says Comscore current share price 'historically undervalued' - 180 Degree Capital Corp. (TURN) issued an analysis that it believes provides substantial support for the preferred stockholders of Comscore (SCOR) to take actions that are within their control to remove or reduce the existing overhang on SCOR's common stock that has led to a material destruction in value since their investment in March 2021. The company said, "Nobody can make you, the preferred stockholders, do anything. That said, having common sense and doing right for all stakeholders at this point should be your only focus, especially if it directly benefits your own economic interests. 180's prior public and private letters focused on the need for changes in SCOR's Board to address the ongoing shortcomings in corporate governance and for the preferred stockholders to take steps that can lead to value creation for all stakeholders, including employees and common stockholders. To date, the Board has sat on its hands and the stock has languished as a result. There is an overriding sentiment that it's impossible to get anything done on this Board because the three preferred stockholders have different agendas and the independent directors are too weak and powerless to do anything. Dispel that myth, please. You all should have one thing in common: that is a desire for a higher share price. So given that common ground, we are encouraging the preferred stockholders and SCOR's Board to do the right thing and immediately start taking action. 180 recognizes and respects the contractual rights of the preferred stockholders and believes these rights are not in conflict with the ability to create value for all stakeholders of SCOR. We believe the mistake every investor has made with regard to this situation is in assuming that preferred holders don't care about the common share price. The fact is, however, that the preferred stockholders' ROI will be significantly enhanced by a share price that is materially higher than it is today. We thought it would be instructive for all stakeholders to understand this point by examining the ROI potential for the preferred stockholders under various valuation and time-based scenarios...It is important to note that we believe SCOR is not in a position where it needs to sell the company, and we are not suggesting that SCOR should pursue this path at this time. As recently as May 16, 2023, at the 18th Annual Needham Technology & Media Conference, Jon Carpenter, CEO of SCOR, noted that SCOR generated positive free cash flow in 2022, has cash to pay the upcoming annual dividend, and expects to generate positive free cash flow in 2023. That said, we do not believe a company in this position would sell at a discounted multiple to its comparable companies, if SCOR's Board chose to pursue a sale of the company...So, we believe investors need not think that SCOR stock price of around $0.90 represents the true and inherent value of this business; in fact, we view the current price as a gift to investors. There is, in our mind, no scenario where SCOR stock isn't meaningfully undervalued relative to its peers. SCOR is running a better business than the one its management team inherited two years ago. SCOR's adjusted EBITDA has gone from approximately $20 million in 2021 to consensus analyst estimates of over $40 million this year and $58 million in 2024, yet the stock has collapsed. Any intellectually honest person would conclude that this improvement in the business would lead to an increased valuation in the public markets. SCOR's preferred stockholders: We have stated in prior letters our thoughts on the reasons why SCOR's share price has collapsed. We have offered suggestions for how you can better align yourself with all stakeholders, but you have taken no action. That inactivity has led to the detriment of your own return on this investment; it is time that you do something. It should be obvious that you have a fixed return unless SCOR's common stock price is meaningfully higher than it is today. Consider that if you take your special dividend in 2024 and continue to hold the preferred stock in future years then your ROI will decline to 12.7% in 2025 and 11.9% in 2026. These ROIs, in our view, are both below market and likely not what you signed up for when you made your investment. We believe our analysis above clearly supports our belief that even without any changes to the terms of SCOR's outstanding preferred stock, SCOR's common stock is significantly undervalued at its current price per share of around $0.90. It is in the best interest of the preferred stockholders to demonstrate better alignment with common stockholders and take actions that will result in a substantial increase in SCOR's common stock price per share. By taking action, you will change the relationship you have with your common stockholders and your ROI will dramatically improve as the stock moves higher."

10:40 EDT Ford says customer wait times to shrink as F-150 Lightning XLT production scales - Ford said it is on track to increase production of the F-150 Lightning at the Rouge Electric Vehicle Center this fall to reduce customer wait times. The high-demand F-150 Lightning XLT model gains the largest initial production increase with new retail orders made today estimated to deliver as early as September. Ford also continues to accept retail customer orders for the Lariat and Platinum models. The F-150 Lightning XLT, with a starting MSRP1 of $64,474, delivers an EPA-estimated range of 2402 miles. The available extended-range battery has an EPA-estimated range of 3203 miles and 580 horsepower4 starting at $78,874. The F-150 Lightning XLT - with standard range battery and most configurations for extended range battery - is eligible for $7,500 in potential federal tax credits. The production increase for the F-150 Lightning is part of Ford's plan to scale electric vehicles and make them more accessible to customers, the company explained. Ford is on track to triple F-150 Lightning production by the end of this year to an annual rate of approximately 150,000 units, to help meet customer demand for the high-tech truck.

10:17 EDT Grainger expands educational assistance program to part-time team members - Grainger announced it has expanded its educational assistance program to include part-time team members and has partnered with new institutions to provide high-quality degree programs, with some offered at no cost. From day one, all team members are eligible to apply to the program, which provides up to $5,250 per year toward a qualifying degree. For annual tuition above that, Grainger splits the cost - covering 50% - with no limit. This also includes specialized technical certifications such as HVAC and OSHA training. If team members have questions about which path to follow, academic advisors are available to discuss schools, majors and programs. In addition, Grainger is expanding its relationships with accredited institutions and has partnered with Western Governors University and the University of Phoenix to offer team members a high-quality education that focuses on adult learners. Many programs through these two universities are offered to Grainger team members at no charge, with others provided at a special, discounted rate.

10:00 EDT Signet Jewelers falls -10.0% - Signet Jewelers is down -10.0%, or -$6.94 to $62.58.

10:00 EDT Smartsheet falls -20.7% - Smartsheet is down -20.7%, or -$10.15 to $38.84.

10:00 EDT Carvana rises 20.3% - Carvana is up 20.3%, or $3.16 to $18.69.

09:59 EDT Ebang International trading halted, volatility trading pause

09:47 EDT Signet Jewelers falls -11.8% - Signet Jewelers is down -11.8%, or -$8.22 to $61.30.

09:47 EDT GameStop falls -19.2% - GameStop is down -19.2%, or -$5.01 to $21.10.

09:47 EDT Carvana rises 20.2% - Carvana is up 20.2%, or $3.14 to $18.67.

09:44 EDT SMX receives delinquency notification letter from Nasdaq - SMX announces that on June 7, 2023, it received a delinquency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market due to the Company's non-compliance with Nasdaq Listing Rule 5450(b)(2)(A) as the market value of the Company's listed securities was less than $50,000,000 for the previous 33 consecutive business days. The Company is addressing the delinquency and is preparing a plan to regain compliance within the 180 calendar day compliance period under Nasdaq rules.

09:41 EDT Knightscope secures two contracts for K5 ASRs - Knightscope announced that it has two new contracts for its K5 Autonomous Security Robots. A southern California convention center and one of Knightscope's Authorized Partners will soon be utilizing the K5s full-time to better protect the places people live, work, study and visit.

09:35 EDT Flat Footed to vote against Diversified Healthcare Trust's proposed merger - Flat Footed, a top shareholder of Diversified Healthcare Trust (DHC) and the owner of approximately 9.4% of the outstanding common shares, filed a preliminary proxy statement with the Securities and Exchange Commission in connection with its opposition to proposals to be presented at the special meeting of shareholders of DHC relating to the Company's proposed merger with Office Properties Income Trust (OPI). Flat Footed said, "DHC's Board of Trustees has not responded to FFL's May 23rd letter, highlighting the numerous reasons why FFL believes DHC shareholders should reject the proposed merger with OPI. The Board has also failed to respond to any of FFL's merger-related questions raised ahead of the Company's Annual Meeting of Shareholders on June 5th. At the Special Meeting, which has yet to be scheduled, FFL intends to vote its DHC shares AGAINST the proposed merger with OPI, as well as the adjournment proposal, to protect the long-term value and interests of all Company stakeholders. FFL's preliminary proxy statement details its serious concerns with DHC's value-destructive proposed merger with OPI."

09:31 EDT BetMGM launches mobile sports betting in Puerto Rico - BetMGM announced the launch of the BetMGM mobile sports betting app in Puerto Rico in partnership with Casino del Mar at La Concha Resort. Puerto Rico is the second market outside of the U.S. mainland for BetMGM's mobile sports betting app.

09:20 EDT Nuvei selected by Sylogist to upgrade payments solution - Nuvei announced its new partnership with Sylogist. Nuvei's payments solution for Software-as-a-Service platforms is enabling Sylogist to offer its customers an enhanced payment experience and accelerate its own growth.

09:16 EDT Muscle Maker says Sadot achieves $9.9M net income threshold - Muscle Maker announced its Sadot subsidiary has crossed the key net income milestone of $9.9M allowing the nomination of the final three new board of director members. As disclosed in an 8K filing on November 18, 2022, MMI and its wholly-owned subsidiary, Sadot LLC, entered into a service agreement whereby Sadot engaged Aggia LLC FZ to perform services related to the purchase of and sale of physical food commodities. Upon Sadot generating certain net income targets, Aggia has the right to nominate up to eight directors and would be issued shares of common stock. Based on successfully meeting previous income targets, Aggia has already appointed five Directors to the MMI board. By crossing the $9.9M threshold, Aggia has the right to nominate three final candidates to the MMI board of directors. Once the three nominations are approved, Aggia will have appointed all eight board members as per the service agreement, bringing the current size of the MMI board of directors to 15. The complete Aggia agreements can be viewed in our 8K filing posted on November 18, 2022. MMI recently announced Sadot May revenue of over $58.9M and a cumulative revenue number of over $418M since Sadot's inception in November 2022.

09:15 EDT Bit Origin mined 29.9 Bitcoins and achieved revenue of $824,645 in May - Bit Origin provided its production and operation update for May 2023. As of May 31 the total mining hash rate stands at 403 PH/s with 4,250 miners installed in the Indiana facility, representing all miners the Company has purchased. Bitcoin Production and Revenue: The Company mined 29.9 Bitcoins and achieved a revenue of $824,645 in May.

09:12 EDT Micron announces 5-year virtual power purchase pact with Terra-Gen - Micron Technology announced it signed a 15-year virtual power purchase agreement for its U.S. operations with Terra-Gen, a developer of renewable energy that operates over 2.2 gigawatt-hours of wind, solar and energy storage throughout the United States. Through the agreement, Micron will receive approximately 178 megawatts of wind electricity capacity and associated renewable energy certificates annually. This contract will support Micron's U.S. target to reach 100% renewable energy by the end of 2025 and marks the latest milestone in Micron's journey to achieve net zero greenhouse gas emissions by 2050."This partnership with Terra-Gen adds another utility-scale renewable energy project to our growing portfolio, supporting our goal to achieve 100% renewable energy in the U.S. by the end of 2025," said Manish Bhatia, executive vice president of Global Operations at Micron. "Terra-Gen's proven track record of building and operating efficient facilities, as well as the maturity of this particular wind project enables Micron to diversify our energy portfolio and to effectively manage our long-term energy costs in the U.S."

09:09 EDT Verses Technologies publishes research on explainable artificial intelligence - VERSES AI announces the publication of a research paper, "Designing Explainable Artificial Intelligence with Active Inference: A framework for interpretability based on the study of introspection and decision-making." The paper articulates methods for developing human-interpretable, explainable artificial intelligence systems based on active inference and the Free Energy Principle, which offers new possibilities for transparency and understanding of AI processing. The research proposes a unique AI architecture based on the active inference framework and the Free Energy Principle. These scientific principles can be used to create an AI that can explain its decision-making process in human-understandable terms - a significant advancement in the era of 'Explainable AI.' A collaboration between researchers from VERSES, the Wellcome Centre for Human Neuroimaging at University College London, the Departments of Cognitive Computing and Philosophy at the Universite du Quebec a Montreal, and the Berlin School of Mind & Brain at Humboldt-Universitat zu Berlin, the paper provides a compelling overview of active inference for modeling decision-making with human-like introspection. The authors contend that their proposed architecture will enable AI systems to track and explain factors contributing to their decisions that can be further scaled up utilizing open standards for knowledge modeling like those being developed by the IEEE Spatial Web Working Group and are intended to be demonstrable in VERSES KOSM OS and GIA products scheduled for release later this year . This new approach to AI transparency aligns with growing demands from regulators, policymakers, and human interest groups for AI systems to be more interpretable and auditable by users.

09:08 EDT E-Home Household Service subsidiary wins RMB10M bid - E-Home Household Services' holding company Zhongrun Pharmaceuticals has won the bid to represent Xi'an Liangjian Technology. The hospital won the bids for Yinerjie, Yinershu and Yinertong, etc. It is expected that Zhongrun Pharmaceuticals will add a total of about RMB30M in hospital business related results this year. Zhongrun Pharmaceuticals also signed a contract with Sanno Biosensing Co. for a hospital clinic generic model product, which is expected to have a turnover of up to RMB10M in Fujian Province within one year.

09:07 EDT Dermata says results of DMT310 Phase 2b study published in peer-reviewed journal - Dermata Therapeutics announced that "positive" results from its DMT310 Phase 2b study of its once-weekly topical treatment in patients with moderate-to-severe acne vulgaris was published in the peer-reviewed Journal of the American Academy of Dermatology. The study found that once-weekly topical treatment with DMT310 resulted in significant improvements across multiple efficacy endpoints at 12 weeks in patients with moderate-to-severe acne when compared with placebo.

09:06 EDT Beneficient lists shares on Nasdaq following merger - Beneficient listed on Nasdaq; its Class A common stock under the ticker "BENF" and its Warrants under the symbol "BENFW". As previously announced, Beneficient completed its business combination with Avalon Acquisition Inc. (AVAC) on June 7, 2023. As a technology-enabled, regulated fiduciary, Beneficient seeks to drive innovation in the market for alternative asset liquidity, which currently exceeds $100 billion in annual demand and is expected to continue growing. While this segment has traditionally been slow to change and caters almost exclusively to large institutional investors, Beneficient focuses on meeting the needs of emerging segments of the market comprised of mid-to-high net worth individual investors and small-to-midsize institutions, with an expected annual, and unmet, demand for liquidity exceeding $50 billion. Beneficient believes future growth will emanate through its breakthrough patent pending technology, including AltAccess and AltQuote. Beneficient expects its technology will provide customers with a secure, online delivery of liquidity payment solutions as well as indicative quotes on the value of their alternative assets. Ben also plans to expand its product and service offerings into complementary products and services including custodying alternative assets, electronic data and physical certificates, data and analytics subscription services, and insurance products and services.

09:04 EDT Synchrony and The Container Store extend consumer financing partnership - Synchrony (SYF) and The Container Store (TCS) announced an expansion and extension of their consumer financing partnership. The multi-year agreement will include integration of a digital private-label credit card and mobile wallet into The Container Store's mobile app check-out capabilities. The Container Store's credit card can be used in conjunction with its Organized Insider loyalty program, allowing cardholders to receive exclusive offers and benefits when they shop with The Container Store credit card.

09:04 EDT Mangoceuticals enters deal with BarStool Sports for 'Only Stans' podcast - Mangoceuticals (MGRX) announce that it has been engaged as a new sponsor for Barstool Sports' (PENN) "Only Stans" podcast. The Company plans on sponsoring at least 8 episodes over the next two months, with more brand involvement potentially in the works.

09:01 EDT Capri Holdings announces 3-year partnership with NFWF - Capri Holdings announced a new 3-year partnership with the National Fish and Wildlife Foundation to accelerate the adoption of voluntary regenerative management and conservation practices in the United States. The initiative is expected to generate $3M in on-the-ground conservation impact through $1.5M in funding from Capri Holdings and matching contributions through NFWF.

08:58 EDT Affirm authorizes repurchase of up to $800M in convertible senior notes due 2026 - In a regulatory filing, the company states: "On June 7, 2023, the board of directors of Affirm Holdings authorized the repurchase of up to $800 million in aggregate principal amount of its outstanding 0% Convertible Senior Notes due 2026. Note repurchases may be made from time to time through December 31, 2023 in privately negotiated transactions. The Company will not receive any cash proceeds from any repurchases of the 2026 Notes. In exchange for paying cash in connection with any such repurchases, the Company will receive and cancel the repurchased 2026 Notes."

08:49 EDT Expion360 launches e360 SmartTalk mobile app - Expion360 launched e360 SmartTalk, a mobile app that allows the integration and management of e360 Bluetooth-enabled lithium iron phosphate batteries. The technology enables users to wirelessly monitor and manage e360 batteries, providing a view of individual battery conditions and performance as well as a comprehensive view of an entire power bank consisting of multiple e360 batteries. The company believes this functionality differentiates the app from others which only allow users to view individual battery conditions.

08:47 EDT Rubicon Technologies reports completion of key strategic finance objective - Rubicon Technologies announced the completion of its final key strategic finance goal, as previously discussed on the company's earnings calls since the fourth quarter of 2022. The new $75M term loan and revolving credit line of up to $90 million were secured through Avenue Sustainable Solutions and MidCap Financial, respectively, and provide significantly enhanced liquidity to the company. Rubicon is confident that it has secured the required financing to take the company through profitability and beyond, and remains on track to achieve its overarching goals of being profitable by the end of this year and generating positive Adjusted EBITDA for the fourth quarter of 2023, as well as for the full year 2024.

08:42 EDT Corning to open glass tubing facility, expand access to Velocity in India - Corning and SGD Pharma today announced a joint venture that includes the opening of a new glass tubing facility to expand pharmaceutical manufacturing in India and allows SGD Pharma to adopt Corning's Velocity(R) Vial technology platform.Combining SGD Pharma's vial-converting expertise with Corning's proprietary glass-coating technology, the collaboration will enhance vial quality, improve filling-line productivity, and speed the global delivery of injectable treatments. SGD Pharma and Corning have broken ground on a new pharmaceutical glass tubing facility in Telangana, India. Together, the two companies will help drugmakers respond to increasingly complex capacity and quality issues while meeting global demand for critical medicines."The partnership with Corning represents yet another step in our strategy to advance converting technology in the pharmaceutical industry and secure our supply chain. The introduction of Velocity Vials will contribute to the ongoing evolution of our offerings and services and will expand our portfolio of high-quality tubular glass packaging," said Olivier Rousseau, CEO SGD Pharma. "We see an opportunity for the industry to improve drug filling quality and performance capabilities by transitioning to Corning's coated vial technology."

08:40 EDT Cemtrex to acquire service contractor and steel fabricator for $2.4M cash - Cemtrex announced that it has entered into a definitive agreement to acquire a leading service contractor and steel fabricator that specializes in industrial and water treatment markets. "This acquisition of an established contractor in a growth market is highly synergistic with our Advanced Industrial Services subsidiary," said Saagar Govil, Cemtrex Chairman and CEO..."The acquisition brings over $11.6M in annual revenue and approximately $775K in adjusted EBITDA. ...Company believes AIS will continue to expand revenues and may exceed its original 3% target of $21.8 million for fiscal year 2023, driven by continued strength in the Industrial Services market. Gross Profit increased 51% to $2.2M and Gross Profit Margin for AIS improved to 36% for the quarter compared to 29% for the prior year...Cemtrex will acquire the company for $2.4M in cash and a note and the real estate the business occupies is also being purchased for $1.5M, subject to customary closing adjustments. Cemtrex will fund the transaction with existing cash on hand and through bank financing from Fulton Bank. The acquisition is expected to close in June 2023, subject to customary closing conditions, and is expected to be accretive beginning in Q4 FY2023.

08:36 EDT Workhorse Group showcases W56 at CALSTART's EV event - Workhorse Group announced it showcased its W56 vehicle to members of Congress, policy makers, and other federal officials at the "Driving the Future: An Electric Vehicle Event" on June 7 in Washington D.C. "Driving the Future: An Electric Vehicle Event" was hosted by CALSTART and members of Congress on the Capitol Grounds and highlighted the availability of a diverse display of electric vehicles.The EV showcase and interactive event allowed members of Congress to learn more about the market readiness and diverse available technology to accelerate the transition to EVs. At the event, Workhorse displayed its W56 delivery vehicle and discussed its use and adoption with attendees who were able to visit, tour, and drive the vehicle.

08:34 EDT Safe & Green: Sale of Lago Vista site 'well underway' - Safe & Green Holdings announced that the auction and planned sale of its Lago Vista site in the greater Austin Texas area is well underway. The initial phase of the auction, conducted by Crexi, a commercial real estate marketplace, generated significant interest and is now closed. The process has now progressed to the next phase of direct negotiations with interested parties. Paul Galvin, Chairman and CEO of Safe & Green Holdings, commented, "Consistent with our strategy to maximize the value of assets, I am quite encouraged by the number of parties and serious interest to purchase our Lago Vista site. We remain confident the site will ultimately be sold for substantially higher than the initial purchase price, providing us additional non-dilutive capital and strengthening our balance sheet. We look forward to providing further updates on the planned sale of the site in the coming weeks."

08:32 EDT Coveo announces official field launch of Coveo Relevance Generative Answering - Coveo announced the official field launch of the Coveo Relevance Generative Answering Design Partner Program with 18 large global customers, giving them access to the beta solution for testing at enterprise scale. Coveo also announced an early adopter offer, limited to current enterprise customers. Today, the product will be unveiled and demonstrated with live enterprise data at the Coveo Relevance 360 event in Menlo Park, California.

08:31 EDT Cano Health board urges shareholders to vote on WHITE proxy card - Cano Health sent a letter to stockholders in connection with its June 15, 2023 Annual Meeting. The company's Board of Directors unanimously recommended that stockholders vote the WHITE Proxy Card "FOR" the re-election of its highly qualified, independent directors and the proposed reverse stock split.

08:25 EDT Upexi's Tytan Magnetic Tiles enters first party agreement with Amazon - Upexi (UPXI) announced that Tytan Magnetic Tiles has entered into a new first party relationship with Amazon.com (AMZN). This strategic partnership will expand Tytan's Disney-Licensed (DIS) and select other product launches for the fourth quarter of 2023 and continue into 2024. The Company anticipates that the combination of the Disney Products powered by Amazon 1P sales initiatives will amplify its presence in the online marketplace and bring its magnetic building sets to a broader audience of parents, educators, and children.

08:22 EDT Graphex Group, Gratomic announce lithium ion battery application results - Gratomic and Graphex Technologies announce that they have jointly submitted samples of vein graphite concentrate from the Aukam Project in Namibia for characterization at an independent laboratory. The aim is to determine whether the graphite is suitable for lithiumion battery anode applications. These test results are critical to establish if Gratomic and Graphex could enter into the next phase of their collaboration. This phase would have the objective to incorporate Aukam Vein Graphite in Lithium Ion Battery Applications that utilize Graphex's competitive technology and expertise in mid-tier processing of graphite for anode materials. Gratomic is currently in step to bring its 100% owned Aukam Vein Graphite processing plant on line by the end of June. Initially, Gratomic will produce 100 tonnes of graphite concentrate as it optimizes its operations for commercial readiness. Deliveries of 100 tonnes of concentrate will be targeted to multiple parties across the world to roll into their applications. The majority will be sent to Graphex's existing full-scale processing facilities to further validate original equipment manufacturers using the material in Li-ion batteries. X-Ray Difraction analysis on an Aukam graphite concentrate sample evaluated key technical aspects of the graphite material such as interlayer spacing, graphite layer thickness, number of graphite monolayers in the flake, average width of the graphite crystal along the a-axis, and degree of graphitization. The results were compared with graphite concentrate from other sources Graphex uses currently for the high value-added processing of anode material and are summarized in Table 1 together with a visual explanation of the XRD data. This comparison indicates the positive potential for processing Aukam Vein Graphite into battery-grade graphite. Accordingly, Gratomic and Graphex will proceed with due diligence discussions of their proposed joint venture to produce coated spherical graphite anode material for the electric vehicle battery market.

08:18 EDT GameSquare Holdings signs with UTA - UTA has signed GameSquare Holdings. With more than 500M+ combined in social following and network of 1,500 talent, GameSquare is helping brands and sports stakeholders to win the attention of young consumers through gaming.

08:17 EDT SOBRsafe partners with MADD to combat teen drunk driving - SOBRsafe has partnered with Mothers Against Drunk Driving to combat drunk driving. The partnership coincides with the launch of the SOBRsure wristband, a sleek, fitness-style wearable that protects against teen drunk driving through: Continuous alcohol monitoring; GPS location tracking; Band removal alerts; A phone-based app for parents.

08:14 EDT UIHC adds BIO-key PortalGuard platform to expand BIO-key investment - BIO-key International announced that its longstanding customer University of Iowa Hospitals & Clinics UIHC would add BIO-key's PortalGuard platform to expand its existing BIO-key biometric authentication investment as it migrates from Epic Systems' legacy Hyperspace application to the new browser-based Hyperdrive interface. UIHC is integrating PortalGuard with Epic Hyperdrive to provide SAML SSO capabilities that leverage their current BIO-key biometric authentication deployment and to avoid user re-enrollment or the adoption of more cumbersome, expensive, or shared multi-factor authentication solutions. Driving the UIHC project timeline is the Epic requirement that customers migrate to Hyperdrive by the November 2023 release deadline.

08:10 EDT ATX Group, Inc. enters into service agreement with SF Express for logistics - Addentax Group's wholly owned subsidiary in China Shenzhen has entered into a logistics service agreement with SF Express, the largest integrated logistics service provider in China and the fourth largest in the world, and a subsidiary of SF Holding. SF Express will be receiving operational logistics services from Addentax across several routes in China, including Shanghai - Dongguan, Shenzhen - Ningbo, Shenzhen - Nanning, Haikou - Sanya, Foshan - Liaocheng, Sanya - Qingyuan, among others. The two parties will collaboratively undertake the transportation tasks required for SF Express's logistics services.

08:09 EDT Ocean Biomedical: Dr. Jonathan Kurtis granted new patent for malaria vaccine - Ocean Biomedical announced that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD has been granted a new patent for his malaria vaccine discoveries that may be used to interdict the parasite at multiple stages in the malaria cycle. This extends patent protection for Dr. Kurtis' novel discoveries that have defined the powerful roles of PfGARP and PfCDPK-5 in controlling the malaria parasite's ability to aggressively multiply within its human host. This patent adds to Ocean Biomedical's global patent portfolio for discoveries with potential to impact major unmet medical needs in infectious disease, oncology, and fibrosis. Ocean Biomedical's breakthrough approach targets the blood-stage portion of the malaria lifecycle - the stage responsible for all clinical disease and death - and therefore has the potential of significantly greater efficacy compared with vaccines targeting other stages. Ocean Biomedical is working to optimize the formulation of this vaccine prior to IND submission and first-in-humans testing. In addition to this multi-pronged vaccine program, Dr. Kurtis has developed a related small molecule drug program to provide a new approach for treating the increasingly drug-resistant strains of malaria. This medicine will be an additional focus of Ocean Biomedical's development pipeline in 2023 and will address a massive unmet need.

08:08 EDT Ameresco JV selected to build 250MW/1,000MWh battery energy storage system - Ameresco announced that its joint venture was selected to build a 250 megawatt, 1,000 megawatt hour battery energy storage system in partnership with Atura Power, a subsidiary of Ontario Power Generation, by the Independent Electricity System Operator in Canada. Ameresco and Atura Power will complete the project through a joint venture known as the Napanee BESS Inc. Pursuant to the award, the JV will enter into a twenty-year capacity agreement with the IESO. In addition to being a 10.1% minority partner in the Napanee BESS Inc. JV, Ameresco will provide Engineering and Construction solutions and expertise for the installation of the BESS under separate contract with the JV. "We are proud that Ameresco was one of the forward-thinking companies that provided the IESO with pilot projects that gave them confidence that BESS systems are ready for prime time at this size," said Lou Maltezos, EVP of Ameresco.

08:07 EDT Marpai announces agreement with Oshi Health - Marpai announces a relationship with Oshi Health to offer the most clinically advanced virtual digestive care to its employer health plan members. The result of rigorous clinical evaluation, this relationship meets the increased urgency of employers to address digestive health concerns and provide access to multidisciplinary digestive care to their employees. Marpai is adding Oshi Health to Marpai Connect, its value-based care network of proven clinical care partners focused on preventing, mitigating, and reversing prevalent, high-cost conditions within health plan populations. Using proprietary AI-powered technology, Marpai proactively informs and educates health plan members facing costly gastrointestinal treatments or procedures, uses multi-channel marketing to drive enrollment, nurtures participating members throughout the process and delivers transparent, detailed reporting to employers. Oshi Health is incentivized to deliver outcomes for members, and employers only pay for program participation by a member.

08:06 EDT Paysign expects to join Russell 3000 Index - Paysign announced it expects to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, based upon the preliminary list of additions announced by FTSE Russell on May 19.

08:05 EDT Proterra appoints Jeffrey Embt as Chief Accounting Officer - Proterra announced the appointment of Jeffrey Embt as Chief Accounting Officer or CAO, effective June 8. As Proterra's CAO, Mr. Embt will report directly to Proterra Chief Financial Officer David Black and oversee the Company's corporate accounting as well as internal control functions and process improvement.

08:05 EDT AES Corp., LineVision announce partnership on Grid Enhancing Technology - The AES Corporation and LineVision announced the launch of a joint project to assess how Grid Enhancing Technologies may increase transmission capacity on the existing power grid. Through this pilot, the companies will gather data using Dynamic Line Ratings to evaluate how LineVision can optimally integrate power from renewable energy sources. The study is being launched this month and will conclude before the end of the year. The project will leverage LineVision's industry leading DLR for a proposed deployment at an AES utility based on a system study to determine locations best suited for the most beneficial impact to the system and customers.

08:03 EDT Vontier selected by Shell to deploy iNFX platform across U.S. network - Vontier Corporation (VNT) announced that its Retail Solutions business has been selected by Shell (SHEL) to deploy its iNFX payment solution and microservices platform across their U.S. network of over 13,000 locations by the end of 2024. "We're grateful for the opportunity to expand our long-standing global partnership with Shell, delivering an innovative, first-to-industry solution that will significantly enhance their forecourt and in-store capabilities," said Karthik Ganapathi, president of Vontier's Retail Solutions business.

08:01 EDT Booz Allen invests in data company Shift5 - Booz Allen Hamilton announced that its corporate venture capital arm, Booz Allen Ventures, LLC, has made a strategic investment in Shift5, the onboard data company. "Shift5 brings order to the complexity of onboard data, providing observability, critical insights, and cybersecurity protection to the world's most critical commercial and military fleets and weapon systems," the company said in a statement. This is the first investment by Booz Allen Ventures aligned with the firm's National Cyber business, it added.

07:56 EDT Hanesbrands reports primary partnership deal with University of Minnesota - Hanesbrands announced a new primary apparel partnership with the University of Minnesota. The 10-year strategic agreement gives HBI exclusive rights to design, manufacture and distribute on-trend fanwear across mass and campus/local retail channels. "As one of the ten largest U.S. universities and an original member of the Big Ten Conference, the University of Minnesota has made its mark on the Midwest and across the world, with dedicated alums and a strong fanbase that revolves around both sports prowess and academic leadership," said John Fryer, President of Licensed Sports Apparel for Hanesbrands. "We're proud to enter this long-term partnership to create dynamic, responsibly made apparel that Golden Gopher fans will love."

07:37 EDT Nextech3D.ai announces Toggle3D goes live - Nextech3D.AI announced that Toggle3D has officially moved out of its public beta and has gone live as of June 8th.

07:36 EDT Bel Fuse divests Stewart Czech business for $5M - Bel Fuse announced the divestment of their Stewart Czech business, part of the Connectivity Solutions segment. The Stewart Czech business consists of two divisions where one operates as a distributor of other connectivity products and the other a manufacturer of copper, fiber and coaxial cable assemblies serving end markets including telecommunications, networking, banking and public administration. The divestiture is deemed to be immaterial to overall Bel operations with ~$5.2M of annual sales.The sale was in the amount of ~$5M. The acquiring business, PEI-Genesis is a long-standing franchise distribution partner of Bel.

07:34 EDT Axon body cameras adopted by Christus Health - Axon announced that Christus Health will equip hospital security officers across their network of hospital campuses with Axon Body 3 body-worn cameras and licenses to Axon's digital evidence management system, Axon Evidence. Christus Health is the tenth largest not-for-profit healthcare system in the U.S. with more than 60 acute health care centers. Christus Health will be outfitting security team members at all U.S. acute care health centers with Axon body-worn cameras.

07:32 EDT SciPlay forms committee to assess acquisition proposal from Light & Wonder - SciPlay (SCPL) has formed a special committee of independent directors co-chaired by Gerald Cohen and April Henry, and with Michael Marchetti and William Thompson serving as members. The Special Committee has been granted full authority to independently review and evaluate the non-binding proposal that the Board received from Light & Wonder (LNW) on May 18, proposing that Light & Wonder acquire the remaining 17% equity interest in SciPlay that it does not already own for $20.00 per share in cash. The company and the Special Committee do not intend to comment further about the Proposed Transaction unless and until they deem further disclosure is appropriate or as required under applicable law.

07:32 EDT Annovis Bio says Phase 3 study of buntanetap has reached full enrollment - Annovis Bio announced that its PD phase III study of its lead compound buntanetap has reached full enrollment in a record nine months after it began. Since the first patient was dosed in late August 2022, over 640 patients were screened and a total of 520 patients enrolled in record time with 67 sites (43 in the United States and 24 in the European Union). The study is expected to conclude in November with top-line assessment data available by the end of the year.

07:25 EDT White Gold files technical report for flagship White Gold Project - White Gold (WHGFOF) filed a technical report in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects to update the Mineral Resource Estimate on its 100% owned flagship White Gold Project. The technical report entitled "2023 Technical Report for the White Gold Project, Dawson Range, Yukon, Canada" and dated May 30, 2023 has been prepared for the Company by Dr. Gilles Arseneau, P.Geo. of ARSENEAU Consulting Services. The technical report is available on SEDAR under the Company's issuer profile. The Project is located approximately 95 km south of Dawson City in west-central Yukon, Canada, and comprises 16 million tonnes averaging 2.23 g/t Au for 1,152,900 ounces of gold in the Indicated Resource category and 19 million tonnes averaging 1.54 g/t Au for 942,400 ounces of gold in the Inferred Resource category. Gold mineralization at the project remains open for expansion along strike and at depth, and opportunities exist to upgrade a significant portion of Inferred Resources to Indicated. Exploration programs supporting the MRE have been backed by partners Agnico Eagle Mines (AEM) and Kinross Gold Corporation (KGC). Highlights: Updated MRE includes four gold deposits - Golden Saddle, Arc, Ryan's Surprise and VG, within 12 km of each other, and comprises: 16.11 million tonnes of Indicated Resources averaging 2.23 grams per tonne gold for 1.153 million ounces of gold, representing 55% of total resources. 18.99 million tonnes of Inferred Resources averaging 1.54 grams per tonne gold for 0.942 million ounces of gold, representing 45% of total resources. Updated MRE includes a maiden resource estimate for the Ryan's Surprise deposit with an Inferred Resource of 227,700 ounces of gold averaging 1.97 grams per tonne gold. The Ryan's Surprise deposit is located 1.5 km west of the Golden Saddle and Arc deposits, and along the Ryan's Trend, a 6.5 km long gold-arsenic geochemical anomaly which hosts additional prospective gold targets. Inferred Mineral Resources have increased by 41% compared to previous MRE's for the Golden Saddle and Arc deposits in 2020 and the VG deposit in 2021. 94% of the resources are near surface, with open-pittable Indicated Resources of 1.125 million ounces of gold averaging 2.20 grams per tonne gold and open-pittable Inferred Resources of 0.853 million ounces of gold averaging 1.46 grams per tonne gold. Mineralization remains open along strike and down dip, with opportunities to further expand and upgrade resources in addition to multiple underexplored targets in close proximity to the deposits. The Company is currently planning its fully funded 2023 exploration program, focusing on recent high-grade gold discoveries and undrilled targets with details to be announced in due course.

07:22 EDT Marathon Gold announces royalty acquisition by Franco-Nevada for $45M - Marathon Gold (MGDPF) announce the sale of an additional 1.5% net smelter returns royalty on its Valentine Gold Project to Franco-Nevada Corporation (FNV) for $45 million, resulting in Franco-Nevada holding an aggregate 3.0% NSR on the Project. In addition, Franco-Nevada has offered to purchase common shares of the Corporation comprising the entire back-end of a C$6.9 million non-brokered charity flow-through offering for which Marathon has firm commitments at a price of C$1.0488 per flow-through share. Marathon intends to use the proceeds of the Offering for eligible exploration expenditures at the Project. The gross proceeds received by the Corporation from the sale of the flow-through shares will be used to incur eligible expenses related to the Project which will constitute "Canadian exploration expenses" as defined in subsection 66.1(6) of the Income Tax Act and which will also qualify as "flow-through mining expenditures" within the meaning of section 127(9) of the Income Tax Act. The CEE will be renounced to the subscribers of the flow-through shares with an effective date of no later than December 31, 2023 in an amount equal to the aggregate purchase price for the flow-through shares. The Offering is being made by way of private placement in Canada. The flow-through shares will be subject to a four month hold period under applicable securities laws in Canada. Closing of the Offering is anticipated to occur on or about July 6, 2023 and is subject to receipt of regulatory approvals, including the approval of the Offering by the Toronto Stock Exchange. RBC Capital Markets is acting as financial advisor to Marathon in connection with the royalty transaction.

07:21 EDT Arvinas announces data from expansion trial of ARV-766 in men with mCRPC - Arvinas announced promising interim data from the Company's Phase 1/2 dose escalation and expansion trial of ARV-766 in men with metastatic castration-resistant prostate cancer, mCRPC. ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor including L702H, a mutation associated with resistance to abiraterone and other AR-pathway novel hormonal agents. The company will provide an overview of these data during a fireside chat at the Jefferies Healthcare Conference today, June 8, 2023, at 11 a.m. ET, which will be available to view in the Investors and Media section of the Arvinas website. Data from the Phase 1/2 dose escalation and expansion trial show that ARV-766 was well-tolerated and demonstrated promising activity in a heavily pre-treated, post-NHA, all-comers patient population..."Tumor resistance mechanisms such as AR LBD mutations are increasing with earlier use of NHAs, leaving limited treatment options for men with prostate cancer in the post-NHA setting," said John Houston, Ph.D., president and chief executive officer at Arvinas. "The patients in this trial received extensive prior therapy for mCRPC and had limited alternative treatment options," said Ron Peck, M.D., chief medical officer at Arvinas. "These data increase our confidence in our ability to bring innovative treatment options to a patient population with significant unmet need. We are excited by the progress in our AR franchise and the potential for bavdegalutamide and ARV-766 to address settings across the continuum of prostate cancer and potentially other AR-driven cancers."

07:19 EDT Onfolio outlines growth, AI strategy in articles posted to site - Onfolio Holdings announces that it posted two articles on its corporate website that provide additional insight into its growth strategy. Specifically, these articles highlight Onfolio's corporate acquisition strategy and its strategy to leverage AI across its subsidiaries. The company said, "Acquisitions and leveraging AI are expected play pivotal roles in the Onfolio's anticipated future growth, and these two articles provide additional transparency and insight into these strategic levers."

07:14 EDT BioCardia announces Helix Biotherapeutic delivery patent issuance in Japan - BioCardia announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled "Radial and Transendocardial Delivery Catheter" with a patent term that will expire on September 30, 2034. This patent describes interventional biotherapeutic delivery catheters to deliver biologics to specific target sites from within the heart chamber. The allowed claims cover BioCardia's helical needle tipped catheter technology platform in existing products and in future products in active development with enhanced features.

07:12 EDT Lava Therapeutics expects cash to fund operations into 2026 - As of March 31, 2023, LAVA had cash, cash equivalents and investments totaling $125.4 million compared to cash, cash equivalents and investments of $132.9 million as of December 31, 2022. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2026.

07:10 EDT Kazia Therapeutics' paxalisib included in Phase II glioma study - Kazia Therapeutics is supporting the University of Sydney on a molecularly-guided phase II clinical study to examine paxalisib in adult patients with recurrent/progressive isocitrate dehydrogenase mutant grade 2 and 3 glioma. The LUMOS2 study aims to investigate paxalisib and other targeted therapies in adult patients with grade 2 or 3 IDH-mutant gliomas. Paxalisib is already the subject of several studies in high-grade glioma, a category which includes diseases such as glioblastoma and Diffuse Intrinsic Pontine Glioma. The study is funded by the Australian Government, through a Medical Research Future Fund grant, with Kazia's contribution consisting of study drug supply and in-kind support. Gliomas are the most common form of primary brain cancer, accounting approximately for a third of malignancies that originate in the brain. The primary objective of the study is to determine progression-free survival at six months with overall survival, response rate and health-related quality of life as secondary endpoints.

07:09 EDT Gritstone publishes results study of samRNA vaccine against COVID-19 - Gritstone announced that interim results from an ongoing Phase 1 study evaluating the company's self-amplifying mRNA vaccine as a boost against COVID-19 were published in Nature Communications. The results, which demonstrate that Gritstone's samRNA vaccine candidate boosted immunity for at least 6 months in previously vaccinated older adults, are generally consistent with initial results from a separate Phase 1 study in previously unvaccinated subjects . Gritstone is currently evaluating multiple samRNA candidates across three ongoing Phase 1 studies. All candidates deliver full-length Spike and selected conserved non-Spike T cell epitopes with the aim of driving a potent, broad, and durable immune response against the virus. "Publication of these results in Nature Communications supports the scientific rigor of our work and potential clinical utility of our next-generation vaccine platform for the prevention of infectious diseases, including coronaviruses, such as COVID-19," said Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone. "The published results are part of a rapidly growing body of evidence demonstrating the potential advantages of samRNA over first-generation COVID-19 vaccines, including extended antigen expression and dose sparing potential. It's clear that new technologies are needed to help prevent and manage future pandemics, and we believe the results we are seeing from our CORAL program represent a promising step forward in this endeavor."

07:09 EDT Cingulate completes Phase 3 adult trial of CTx-1301 in ADHD - Cingulate announced it has completed its Phase 3 adult dose-optimization trial of its lead candidate, CTx-1301, a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder, upon approval from the U.S. Food and Drug Administration. The Phase 3 CTx-1301-022 study assessed the onset and duration of CTx-1301 in 21 adults with ADHD in an adult laboratory classroom setting. Results from the trial are expected in 3Q 2023 and will be submitted for presentation at a future medical meeting. In addition to the Phase 3 adult dose-optimization study, Cingulate plans to initiate its pivotal Phase 3 fixed-dose pediatric and adolescent study and its pivotal dose-optimization onset and duration trial in pediatric patients in 3Q 2023. Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit a New Drug Application for CTx-1301 in mid-2024 under the Section 505(b)(2) pathway.

07:07 EDT Bausch + Lomb to present 11 scientific poster presentations at AOA meeting - Bausch + Lomb announced that researchers will present the results of 11 scientific poster presentations involving the company's consumer, vision care and pharmaceutical products during the American Optometric Association Optometry's Meeting e-posters Virtual Event, which is taking place from June 13-14, 2023. In addition, the company will host several sponsored education events at the Optometry's Meeting in Washington, D.C. from June 21-24, 2023. The poster presentations will include data from the two pivotal Phase 3 trials, GOBI and MOJAVE, and 12-month KALAHARI safety extension study of MIEBO. MIEBO was approved by the U.S. Food and Drug Administration on May 18, 2023, for the treatment of the signs and symptoms of dry eye disease. It is the first and only FDA approved prescription eye drop that directly targets tear evaporation in individuals with DED. Three posters will highlight the benefits of new Biotrue Hydration Boost Contact Lens Rehydrating Drops, and two others will feature new data on our recently launched Bausch + Lomb INFUSE Multifocal silicone hydrogel daily disposable contact lenses designed for presbyopic patients: a comparison of the power profiles across the near, intermediate and distance vision zones and an eye care practitioner fitting assessment of the lens.

07:07 EDT Canadian Solar's CSI Energy selected to provide battery storage in U.K. - Canadian Solar announced that CSI Energy Storage, part of its majority-owned subsidiary CSI Solar, has entered into a supply agreement with Unibal, a joint venture between Union Group and Capbal Limited, to deliver battery storage systems for two projects totaling 40 MWh in the U.K. The projects are expected to reach commercial operation in Q1 2024. Unibal Energy Limited is a UK based company focused on acquisition, origination, construction and operation of renewable generation and energy storage assets across the UK. CSI Energy Storage will deliver its SolBank battery energy storage systems and provide the full integration and commissioning services. CSI Energy Storage has also secured the long-term service agreements for the projects. As of March 31, 2023, CSI Energy Storage's total pipeline has reached nearly 22.8 GWh.

07:05 EDT Rev Group board approves new $175M share repurchase authorization - On June 1, 2023, the company's board of directors approved the repurchase of up to $175.0 million of the company's outstanding common stock. This new authorization replaces the previous $150.0 million repurchase program, which was terminated by the board of directors in connections with the new authorization, under which approximately $73.7 million of the company's common stock had been repurchased since its authorization in September 2021. The new share repurchase authorization expires in 24 months and gives management flexibility to determine conditions under which the shares may be purchased.

07:03 EDT Rocket Pharmaceuticals receives FDA fast track, ODD for RP-A601 - Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track and Orphan Drug designations to RP-A601, the company's gene therapy candidate for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy. RP-A601 is Rocket's adeno-associated virus-based gene therapy for PKP2-ACM, a devastating, inherited heart disease associated with life-threatening arrhythmias, cardiac structural abnormalities, and sudden cardiac death. The current standard of care consists of medical therapy, implantable cardioverter defibrillators, and ablation procedures, none of which are curative. Even with treatment, life-threatening arrhythmias and progression of disease can still occur. PKP2-ACM affects approximately 50,000 people in the U.S. and Europe. Rocket recently announced FDA clearance of the Investigational New Drug application for RP-A601 based on robust preclinical proof of concept studies that demonstrated decreased arrhythmias and increased survival. RP-A601 is the first gene therapy in development for PKP2-ACM to receive IND clearance and the second of three programs in the Company's AAV-based cardiovascular gene therapy franchise. The company is initiating a multi-center Phase 1, dose escalation trial that will evaluate the safety and preliminary efficacy of RP-A601 in at least six adult PKP2-ACM patients with ICDs and who have overall high risk for life-threatening arrhythmias. The study will assess the impact of RP-A601 on PKP2 myocardial protein expression, cardiac biomarkers, clinical predictors of life-threatening ventricular arrhythmias, and sudden cardiac death.

07:02 EDT SSR Mining announces CEO Rodney Antal to succeed Michael Anglin as chairman - SSR Mining announced a leadership transition as part of its planned Board of Directors succession process. Michael Anglin, Chairman of the Board, has made the decision to retire after serving for over 15 years on the SSR Mining Board, and will not stand for re-election at the company's 2024 Annual Meeting of Shareholders. The Board of Directors has unanimously appointed Rodney Antal, SSR Mining's President and CEO, as the new Executive Chairman. Anglin will take on the position of Lead Independent Director until the 2024 AGM. Upon his retirement, a new Lead Independent Director will be appointed. SSR Mining's Board of Directors remains steadfast in its commitment to a seamless leadership transition. The Board takes an active approach to managing Board composition and succession planning and Anglin's retirement marks the next phase of the planned succession process.

06:58 EDT International Game reviews strategic alternatives for Global Gaming, PlayDigital - International Game Technology Board of Directors is evaluating potential strategic alternatives for IGT's Global Gaming and PlayDigital segments in order to unlock the full value of IGT's portfolio. IGT's Board of Directors is considering a broad range of potential alternatives, including but not limited to a sale, merger or spin-off, as well as retaining and further investing in the Global Gaming and PlayDigital businesses. IGT has retained Deutsche Bank, Macquarie Capital and Mediobanca as financial advisors and Sidley Austin and White & Case are serving as legal counsel to assist IGT in exploring strategic alternatives. No decision has been made regarding any alternative, there is no timeline for the review and there can be no assurance that the exploration of strategic alternatives will result in any transaction. IGT does not intend to comment on or provide updates regarding these matters unless and until it determines that further disclosure is appropriate or required.

06:57 EDT Aecom to manage delivery of green hydrogen facility expansion in France - Aecom has been appointed to oversee the delivery of the expansion of The Chemours Company's green hydrogen production facility in the Villers-Saint Paul region of France. The expansion will allow Chemours to increase capacity and advance technology of its Nafion Ion Exchange materials platform, a key component for electrolysers to produce green hydrogen. Aecom has previously undertaken similar project management services for Chemours in the U.S. Aecom is also engaged in supporting Chemours at the Villers-Saint-Paul site with permitting support through Aecom 's Environment team.

06:52 EDT Designer Brands to repurchase up to $100M shares in tender offer - Designer Brands announced that its Board of Directors has authorized the repurchase of up to $100 million of the Company's Class A common shares through a modified "Dutch Auction" tender offer, at an anticipated cash purchase price of not less than $7.00 per share and not more than $8.00 per share, less any applicable withholding taxes and without interest. Designer Brands intends to enter into a $135 million term loan agreement to be used principally to fund the Offer, with the remaining availability to be used for general corporate purposes. Designer Brands intends to commence the Offer later today, on June 8, 2023, with expiration of the Offer scheduled for 12:00 Midnight, at the end of the day, New York City time on Friday, July 7, 2023, unless the Offer is extended or terminated. The Offer is expected to be subject to certain conditions, including the Financing Contingency, which must be consummated in order to fund the Offer.

06:46 EDT Stantec to acquire Environmental Systems Design, terms not disclosed - Stantec has signed an agreement to acquire Environmental Systems Design, a 270-person engineering firm headquartered in Chicago. Founded in 1967, ESD has built a reputation for excellence and innovation in high-performance design with a roster of industry-leading clients. The terms of the transaction are not disclosed.

06:32 EDT Nxu Inc. names Jordan Christensen as Chief Legal Officer - Nxu Inc. announced the appointment of Jordan Christensen to the company's executive team as Chief Legal Officer, effective June 5. Reporting directly to Chairman and CEO Mark Hanchett, Christensen will oversee the company's legal, compliance and regulatory affairs functions, including corporate governance, securities, and corporate finance, commercial, litigation, labor and employment, and intellectual property matters. He joins the company from WCAZ Law, PLLC, where he was a managing partner acting as outside general counsel for a number of early-phase start-up companies since 2018.

06:09 EDT Gogoro's Smart Traffic Signal UPS to be rolled out in Taipei City - Gogoro and Far EasTone Telecom are deploying their jointly-developed Smart Traffic Signal Uninterruptible Power System - UPS - to nearly 200 of Taipei City's busiest intersections utilizing Gogoro Smart Batteries. The commercial rollout follows the completion of a successful pilot program in 2022. The Smart Traffic Signal UPS was designed for densely populated cities, like Taipei City, that rely on continuous operation of traffic intersections and want to ensure 24/7 operations during severe weather, natural disasters, or power grid outages. The Smart Traffic Signal UPS provides long term supplemental energy using two Gogoro Smart Batteries that can be swapped without disruption to maintain continuous operation as long as necessary. The system has already been deployed to 25 of Taipei City's busiest intersections and will roll out to nearly 200 intersections by the end of the year.

06:06 EDT Clean Energy signs new carbon reducing fueling agreements - Clean Energy announced a slew of new deals with several wellconsumer brands and some of the nation's largest transit agencies. Liberty Coca-Cola, one of the country's largest bottlers, has signed a fueling contract with Clean Energy to power trucks in New York and Philadelphia with renewable natural gas. Electrolux North America has signed a fueling agreement with Clean Energy for an estimated 200,000 gallons of RNG at Clean Energy's station in Ontario, CA. Recology, a waste management company, has inked new and extended RNG supply and maintenance contracts for an anticipated 800,000 and 6.5 million gallons respectively. Recology has contracted Clean Energy to build a new RNG station In Snohomish, WA that is projected to fuel 30 trucks. The Big Blue Bus in Santa Monica, CA has signed a maintenance agreement for its fleet of 195 transit buses that fuels with an anticipated 7.5 million gallons of RNG. Clean Energy has been contracted by Gold Coast Transit to maintain its station in Oxnard, CA which uses an estimated 4 million gallons of RNG for 82 transit buses. Channel Island Dairy Farms has signed a contract for an estimated 300,000 gallons of RNG for heavy-duty trucks operating in the Corcoran, CA area. The Birmingham Jefferson County Transit Authority has signed a maintenance agreement with Clean Energy for its Birmingham, AL station. The City of Tucson has signed a maintenance agreement with Clean Energy to support its fleet operations. Grand Canyon National Park, AZ has signed an agreement with Clean Energy to maintain its station. The station is anticipated to provide 1.5 million gallons of fuel for 30 park shuttle buses. Campbell's Trucking Company in Tacoma, WA has signed a fueling deal for an expected 300,000 gallons of fuel for 15 heavy-duty trucks.

06:05 EDT Hooker Furniture increases share repurchase plan by $5M - "We're pleased with the progress we've made reducing inventories, which was a large part of the cash we generated during the quarter. Since the repurchase program's announcement around this time last year, we have returned approximately $20 million to our shareholders and retired 1.2 million shares. Our board recently approved an additional $5 million authorization as part of our capital allocation plan for this year. In addition to continuing to execute the share repurchase plan, our capital allocation priorities include building cash reserves, funding the organic growth initiatives noted earlier, continuing our dividend, and funding typical capital expenditures," Huckfeldt concluded.

06:02 EDT Autoliv accelerates structural cost reduction measures, backs 2023 guidance - Autoliv is accelerating its global structural cost reductions, particularly within its European operations and reiterates its full year 2023 indications. The accelerated structural cost reduction initiatives include further optimization of the company's geographic footprint and organizational structure, including a substantial reduction of its total direct and indirect workforce by up to 11%. Autoliv intends to close several sites in Europe. These initiatives are expected to reduce up to 2,000 indirect positions globally, or around 11% of Autoliv's total indirect workforce. Of this, up to 1,000 are expected to be in Europe. All divisions and functions will be impacted by these initiatives and the company expects the first headcount reductions to occur in 2023. The company also intends to reduce its global direct headcount by around 6,000 positions globally, or around 11% of total direct workforce. The company expects to accrue a minor part of the total accrual in Q2. The initiatives are expected to be fully implemented by 2025 and to have a pay-back time of 1-2 years. The company continues to negotiate with its customers to secure pricing that reflects inflation and structural price gaps. Autoliv reiterates its 2023 outlook of 8.5-9.0% adjusted operating margin and operating cash flow of around $900M.

05:56 EDT BlackRock to acquire Kreos Capital, terms not disclosed - BlackRock and Kreos Capital announced a definitive agreement under which BlackRock will acquire full control of Kreos, a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. Kreos is headquartered in London and its 45-person team, which will join BlackRock as part of the transaction, has demonstrated strong performance over a 24-year track record. Kreos' investment team will integrate into BlackRock's European Private Debt platform and current Kreos leadership will continue to be responsible for executing on the firm's proven investment strategies. The transaction, which is expected to close in Q3 2023, is subject to customary regulatory and closing conditions. The financial impact of the transaction is not material to BlackRock earnings.

05:53 EDT Astellas Pharma, Kate Therapeutics sign license agreement for KT420 - Astellas Pharma and Kate Therapeutics announced an exclusive license agreement to develop and commercialize KT430. KT430 is a preclinical next-generation investigational gene therapy that delivers a functional copy of the MTM1 gene via a novel MyoAAV capsid to treat X-linked myotubular myopathy, a serious, life-threatening, rare neuromuscular disease characterized by extreme muscle weakness, respiratory failure and early death. Under the terms of the agreement, Astellas will make an undisclosed upfront payment to KateTx, which is also eligible to receive development, regulatory and commercial milestone payments, plus royalties on worldwide sales. Astellas will receive an exclusive worldwide license to develop, manufacture and commercialize KT430.